Lipocine reports Q3 EPS ($1.27), consensus (60c)

During Q3 the Company recognized a non-cash minimum guaranteed royalties revenue reversal of variable consideration revenue of $3.1M related to the termination of the Antares License Agreement. The reversal of revenue is due to the fact that Lipoocine will not receive anticipated royalties that were previously recorded for the Antares License Agreement due to the termination of the agreement. Consensus is for Q3 revenue $470,000.